---
title: "MEDICUS PHARMA LTD C/WTS 15/11/2029(TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/265982841.md"
datetime: "2025-11-14T21:09:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/265982841.md)
  - [en](https://longbridge.com/en/news/265982841.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/265982841.md)
generator: "portal-rs"
---

# MEDICUS PHARMA LTD C/WTS 15/11/2029(TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 0

Revenue: As of FY2025 Q3, the actual value is USD 0.

EPS: As of FY2025 Q3, the actual value is USD -1.12.

EBIT: As of FY2025 Q3, the actual value is USD -15.44 M.

### Segment Revenue

Medicus Pharma Ltd. reported no revenue from its preclinical programs, as it is considered to be in the R&D stage.

### Operational Metrics

-   **Net Loss**: For the three months ended September 30, 2025, the net loss was - $15,981,312, compared to - $2,278,747 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was - $27,259,804, compared to - $7,618,964 for the same period in 2024.
-   **Operating Expenses**: Total operating expenses for the three months ended September 30, 2025 were $15,426,340, compared to $2,334,261 for the same period in 2024. For the nine months ended September 30, 2025, total operating expenses were $26,568,702, compared to $7,595,453 for the same period in 2024.

### Cash Flow

-   **Operating Cash Flow**: Net cash used in operating activities for the nine months ended September 30, 2025 was - $16,167,654, compared to - $7,055,679 for the same period in 2024.
-   **Free Cash Flow**: Not explicitly stated, but the net increase in cash and cash equivalents during the period was $4,497,768.

### Unique Metrics

-   **Debentures**: On September 17, 2025, a new debenture was issued with a principal amount of $8,000,000 at a discounted price of 90%, with interest accruing at an annual rate of 8%.

### Future Outlook and Strategy

-   **Core Business Focus**: The company plans to continue its clinical trials, including SKNJCT-003 and SKNJCT-004, and anticipates increased R&D expenses as these trials progress.
-   **Non-Core Business**: The company completed the acquisition of Antev Limited, acquiring 98.6% of its shares, and plans to integrate Antev’s assets, including Teverelix, into its operations.
-   **Priority**: The company is focused on securing additional capital through public and private equity offerings, debt financings, and strategic alliances to support its ongoing R&D activities and potential commercialization efforts.

### Related Stocks

- [MDCXW.US](https://longbridge.com/en/quote/MDCXW.US.md)

## Related News & Research

- [Is Camtek (CAMT) Options Frenzy Quietly Reframing Its Near‑Term Earnings Story?](https://longbridge.com/en/news/298114664.md)
- [The Bull Case For Natera (NTRA) Could Change Following New Signatera Lymphoma Data And Komen Partnership](https://longbridge.com/en/news/298111249.md)
- [Stronger Q2 Results And Raised 2026 Outlook Could Be A Game Changer For IDEXX Laboratories (IDXX)](https://longbridge.com/en/news/298111178.md)
- [NBH Bank Makes New Investment in Bank of America Corporation $BAC](https://longbridge.com/en/news/298108822.md)
- [MW Advisory LLC Makes New $1.77 Million Investment in Visa Inc. $V](https://longbridge.com/en/news/298108585.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**